Shots:

• The EC has approved MB02 biosimilar to Avastin (Bevacizumab) in the EU for the treatment of carcinoma of the colon or rectum- BC- NSCLC- RCC- epithelial ovarian- fallopian tube or primary peritoneal cancer- and carcinoma of the cervix
• Mabxience’s MB02 to be marketed as Alymsys and Oyavas both show comparable quality- safety & efficacy to Avastin (bevacizumab)
• The launch of Bevacizumab has provided high quality- affordable medicine and opportunity to the healthcare system and improve patient access to biological treatments throughout the EU

  Ref: PRNewswire | Image: Adobe Stock